item management s discussion and analysis of financial condition and results of operations the company has generated limited revenues from product sales and has been dependent upon external financing  interest income  and research and development contracts to pursue its intended business activities 
the company has not been profitable since inception and has incurred a cumulative net loss of  through december  losses have resulted principally from costs incurred in research activities aimed at identifying and developing the company s product candidates  clinical research studies  merger and acquisition costs  the write off of purchased research and development  and general and administrative expenses 
the company expects to incur additional operating expenses over the next several years as the company s research and development and clinical trials programs continue 
the company s ability to achieve profitability is dependent on the level of revenues from the sale of drug substance to support lotemax and alrex coupled with its ability to develop and obtain regulatory approvals for its product candidates  to enter into agreements for product development and commercialization with strategic corporate partners and to develop the capacity to manufacture and sell its products  and to secure additional financing 
see management s discussion and analysis of financial condition and results of operations liquidity and capital resources 
results of operations years ended december  and total operating expenses increased by  or  from  in to  in overall  the net decrease was related to bulk material purchases of loteprednol etabonate le  the active drug substance of lotemax and alrex  which was principally offset by reductions in other operating expenses related to the filing of nda s for lotemax and alrex 
net research and development expenses decreased by  or  from  in to  in the completion of the clinical trials associated with the company s nda submissions for le resulted in a decrease in r d expense 
the company increased participation in approved r d reimbursement programs which contributed to a reduction in r d expense 
increased costs for toxicology studies for the le t program a combination of le and tobramycin and dexanabinol  as well as activities to advance the manufacturing of le  partially offset the decrease in r d expense 
in anticipation of approval by the fda of the ndas for lotemax and alrex and in accordance with its obligations under the marketing agreements to supply bausch lomb with certain specified quantities of le the active drug substance  the company purchased quantities of le and smaller quanitities of a key reagent required for the manufacture of le  in the amount of  certain purchases of le  totaling  have been expensed in this amount represents inventory to be used in testing  manufacturing and various marketing programs 
on september   the company signed an agreement terminating the licensing agreement with the university of florida  and returned the rights to technologies that the company had previously ceased developing 
the termination agreement included a waiver of  in outstanding debts due the university 
patent expenses decreased by  or  from  in to  in this decrease is due to the timing of completion of certain patent applications 
general and administrative expense decreased by  or  from  in to  in lower expenses associated with the completion of the company s ndas for lotemax and alrex as well as the closure of its florida facility were primarily responsible for the decreased general and administrative costs 
depreciation and amortization expenses decreased by  or  from  in to  in  reflecting reduced depreciation expense relating to the alachua  florida operation 
interest and other income  net of interest and other expenses  increased by  or  from  in to  in interest and other income  net  increased as a result of higher average cash balances  favorite transaction gains and the waiver of outstanding debts to the university of florida 
years ended december  and total revenues decreased by  from revenues in related to fees the company received as a result of sublicensing certain technologies which were not being actively developed by the company 
total operating expenses increased by  or  from  in to  in due to increased research and development spending partially offset by lower general  administrative and other expenses 
research and development expenses increased by  or  primarily due to significant spending on clinical trails in during the past year  the company initiated and completed phase iii clinical trials of lotemax for the treatment of uveitis and post cataract surgery as well as phase iii clinical trials of alrex for the treatment of seasonal ocular allergies 
in october of  the company commenced a phase ii study of hu for severe head injury 
in february  the company submitted an nda for alrex and in march  the company amended and supplemented the previously filed nda for lotemax with the results of the clinical trials 
the increased clinical trial expenses were partially offset by cost saving measures taken by the company in early that focused research and development activities on products which were closest to commercialization 
bausch lomb net reimbursements for clinical trials totaled million during  thereby reducing research and development expenses by this amount 
patent expense decreased by  or  in the company was able to reduce patent maintenance costs by returning to an original patent holder several patents covering technologies which are no longer being pursued 
further  the company s in house patent counsel now executes work previously undertaken by external patent attorneys 
general and administrative costs decreased by  or  in this reduction resulted primarily from the relocation of corporate headquarters from new york to the company s existing facility in alachua  florida 
depreciation and amortization expenses decreased by  or  in due to the absence in of depreciation of new york facilities following the closing  a write off of certain leasehold improvements  as well as reduced depreciation relating to the florida operation 
net interest income increased by  in  reflecting the higher level of investable funds in in addition  the company had higher interest expense in relating to interest on the convertible debentures issued by the company in february  and converted into common stock by july  and a note that was paid in full 
liquidity and capital resources the company has had no sources of recurring revenues and has incurred operating losses since its inception 
at december   the company has an accumulated deficit of  the company has financed its operations with public and private offerings of securities  advances and other funding pursuant to a marketing agreement with bausch lomb  research contracts  license fees  royalties and sales  and interest income 
the company had working capital of million  including cash and cash equivalents of million  as of december  on february   the company completed a private placement of convertible preferred stock and warrants that generated million in gross proceeds 
management believes that existing cash and cash equivalents combined with anticipated cash inflows from investment income  r d grants and proceeds from sales of the drug substance for lotemax and alrex to bausch lomb will be sufficient to support operations through the first quarter of the company is continuing to actively pursue various funding options  including additional equity offerings  strategic corporate alliances  business combinations and the establishment of product related research and development limited partnerships  to obtain the additional financing that would be required to continue the development of its products and bring them to commercial markets 
the company s success depends upon many factors that are beyond the company s immediate control  including market acceptance of lotemax and alrex  competition  and the ability to obtain additional financing 
there can be no assurance that lotemax or alrex will achieve market acceptance or that the company will be successful in obtaining additional financing or commercializing its product candidates 
during  the company raised additional equity of million through the issuance of common stock  convertible preferred stock and warrants 
all net proceeds were available to fund the company s operations 
pursuant to the us marketing agreement with bausch lomb and following the nda submission for alrex  the company received in march  an additional million in advances against future sales of the active drug substance needed to manufacture the drug   of which was advanced to the license holder 
cumulative advances from bausch lomb as of december  total million 
bausch lomb will be entitled to recoup the advances by way of credits from future sales of lotemax  alrex and line extension products 
the company may be obligated to repay such advances if it is unable to supply bausch lomb with certain specified quantities of the active drug substance 
the year management believes  based on available information  that it will be able to manage its year transition for systems and infrastructure without any material adverse effect on its business operations  products or financial prospects 
there can be no assurance  however  that a failure to resolve any issue relating to such transition would not have a material adverse effect on the company 

